Jerrie S. Refuerzo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jerrie S. Refuerzo has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Sean C. Blackwell
Dept. of OB/GYN, McGovern Medical School at UTHealth, Houston, TX
11 shared publications - Monica Longo
Dept. of OB/GYN, McGovern Medical School at UTHealth, Houston, TX
8 shared publications Baha M. Sibai
Dept. of OB/GYN, McGovern Medical School at UTHealth, Houston, TX
7 shared publications- Biana Godin
Center for BioNanoengineering, Houston Methodist Hospital, Houston, USA
5 shared publications - Alejandra Elder Ontiveros
Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA; Program in Developmental Biology, Baylor College of Medicine, Houston, Texas, 77030, USA
3 shared publications Fangxian Lu
Dept. of OB/GYN, McGovern Medical School at UTHealth, Houston, TX
3 shared publications
Latest Publications
- 1 December 2017
- Published by Wolters Kluwer Health in Obstetric Anesthesia Digest
- Vol. 37 (4) , 181
Targeted Nanoparticles in Pregnancy: A New Frontier in Perinatal Therapeutics
- 1 December 2017
- Published by Wolters Kluwer Health in Obstetric Anesthesia Digest
- Vol. 37 (4) , 181
Targeted Nanoparticles in Pregnancy: A New Frontier in Perinatal Therapeutics
- Open Access
- 23 March 2017
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (4) , 683
Magnetically Bioprinted Human Myometrial 3D Cell Rings as A Model for Uterine Contractility
Deregulation in uterine contractility can cause common pathological disorders of the female reproductive system, including preterm labor, infertility, inappropriate implantation, and irregular menstrual cycle. A better understanding of human myometrium contractility is essential to designing and testing interventions for these important clinical problems. Robust studies on the physiology of human uterine contractions require in vitro models, utilizing a human source. Importantly, uterine contractility is a three-dimensionally (3D)-coordinated phenomenon and should be studied in a 3D environment. Here, we propose and assess for the first time a 3D in vitro model for the evaluation of human uterine contractility. Magnetic 3D bioprinting is applied to pattern human myometrium cells into rings, which are then monitored for contractility over time and as a function of various clinically relevant agents. Commercially available and patient-derived myometrium cells were magnetically bioprinted into rings in 384-well formats for throughput uterine contractility analysis. The bioprinted uterine rings from various cell origins and patients show different patterns of contractility and respond differently to clinically relevant uterine contractility inhibitors, indomethacin and nifedipine. We believe that the novel system will serve as a useful tool to evaluate the physiology of human parturition while enabling high-throughput testing of multiple agents and conditions.
- 23 March 2017
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (4) , 683
Open AccessMagnetically Bioprinted Human Myometrial 3D Cell Rings as A Model for Uterine Contractility
Deregulation in uterine contractility can cause common pathological disorders of the female reproductive system, including preterm labor, infertility, inappropriate implantation, and irregular menstrual cycle. A better understanding of human myometrium contractility is essential to designing and testing interventions for these important clinical problems. Robust studies on the physiology of human uterine contractions require in vitro models, utilizing a human source. Importantly, uterine contractility is a three-dimensionally (3D)-coordinated phenomenon and should be studied in a 3D environment. Here, we propose and assess for the first time a 3D in vitro model for the evaluation of human uterine contractility. Magnetic 3D bioprinting is applied to pattern human myometrium cells into rings, which are then monitored for contractility over time and as a function of various clinically relevant agents. Commercially available and patient-derived myometrium cells were magnetically bioprinted into rings in 384-well formats for throughput uterine contractility analysis. The bioprinted uterine rings from various cell origins and patients show different patterns of contractility and respond differently to clinically relevant uterine contractility inhibitors, indomethacin and nifedipine. We believe that the novel system will serve as a useful tool to evaluate the physiology of human parturition while enabling high-throughput testing of multiple agents and conditions.
- 1 March 2017
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 216 (3) , 204-205
Targeted nanoparticles in pregnancy: a new frontier in perinatal therapeutics
- 1 March 2017
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 216 (3) , 204-205
Targeted nanoparticles in pregnancy: a new frontier in perinatal therapeutics
- 1 January 2017
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 216 (1) , S487-S488
851: Maternal metabolic syndrome and hypertension altered TNFα and mTOR1 activity in the cerebellum of adult offspring: implications for autism-spectrum disorder
- 1 January 2017
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 216 (1) , S487-S488
851: Maternal metabolic syndrome and hypertension altered TNFα and mTOR1 activity in the cerebellum of adult offspring: implications for autism-spectrum disorder
- 1 January 2017
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 216 (1) , S488
852: Effect of inositol supplementation during pregnancy on neurobehavioral outcome of offspring born to pregnant dams with metabolic syndrome
- 1 January 2017
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 216 (1) , S488
852: Effect of inositol supplementation during pregnancy on neurobehavioral outcome of offspring born to pregnant dams with metabolic syndrome
- 1 January 2017
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 216 (1) , S319-S320
541: Investigating the mechanisms leading to improved metabolic profile by inositol in pregnancy complicated by metabolic syndrome
- 1 January 2017
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 216 (1) , S319-S320
541: Investigating the mechanisms leading to improved metabolic profile by inositol in pregnancy complicated by metabolic syndrome
- 1 January 2017
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 216 (1) , S501-S502
878: Does maternal treatment of non-severe hypertension with sildenafil improve vascular function in their adult offspring?
- 1 January 2017
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 216 (1) , S501-S502
878: Does maternal treatment of non-severe hypertension with sildenafil improve vascular function in their adult offspring?
- 1 January 2017
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 216 (1) , S75-S76
106: Does maternal treatment of metabolic syndrome with inositol improve vascular function in their adult offspring?
- 1 January 2017
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 216 (1) , S75-S76
106: Does maternal treatment of metabolic syndrome with inositol improve vascular function in their adult offspring?
- 1 January 2017
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 216 (1) , S501
877: Sildenafil treatment of non-severe hypertension during pregnancy alters placental protein expression involved in angiogenesis
- 1 January 2017
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 216 (1) , S501
877: Sildenafil treatment of non-severe hypertension during pregnancy alters placental protein expression involved in angiogenesis
- Open Access
- 11 October 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 34710
Uterus-targeted liposomes for preterm labor management: studies in pregnant mice
Preterm labor caused by uterine contractions is a major contributor to neonatal morbidity and mortality. Treatment intended to reduce uterine contractions include tocolytic agents, such as indomethacin. Unfortunately, clinically used tocolytics are frequently inefficient and cross the placenta causing fetal side effects. Here we show for the first time in obstetrics the use of a targeted nanoparticle directed to the pregnant uterus and loaded with a tocolytic for reducing its placental passage and sustaining its efficacy. Nanoliposomes encapsulating indomethacin and decorated with clinically used oxytocin receptor antagonist were designed and evaluated in-vitro, ex-vivo and in-vivo. The proposed approach resulted in targeting uterine cells in-vitro, inhibiting uterine contractions ex-vivo, while doubling uterine drug concentration, decreasing fetal levels, and maintaining the preterm birth rate in vivo in a pregnant mouse model. This promising approach opens new horizons for drug development in obstetrics that could greatly impact preterm birth, which currently has no successful treatments.
- 11 October 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 34710
Open AccessUterus-targeted liposomes for preterm labor management: studies in pregnant mice
Preterm labor caused by uterine contractions is a major contributor to neonatal morbidity and mortality. Treatment intended to reduce uterine contractions include tocolytic agents, such as indomethacin. Unfortunately, clinically used tocolytics are frequently inefficient and cross the placenta causing fetal side effects. Here we show for the first time in obstetrics the use of a targeted nanoparticle directed to the pregnant uterus and loaded with a tocolytic for reducing its placental passage and sustaining its efficacy. Nanoliposomes encapsulating indomethacin and decorated with clinically used oxytocin receptor antagonist were designed and evaluated in-vitro, ex-vivo and in-vivo. The proposed approach resulted in targeting uterine cells in-vitro, inhibiting uterine contractions ex-vivo, while doubling uterine drug concentration, decreasing fetal levels, and maintaining the preterm birth rate in vivo in a pregnant mouse model. This promising approach opens new horizons for drug development in obstetrics that could greatly impact preterm birth, which currently has no successful treatments.